Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting.
Reichardt P, Schlemmer M, Delgado Perez JR, Papai Z, Prausova J, Melichar B, Fumagalli E, Barone C, Bauer S, Pustowka A, Crippa S, Castellana R, Quiering C, Le Cesne A. Reichardt P, et al. Among authors: fumagalli e. Oncol Res Treat. 2019;42(12):629-635. doi: 10.1159/000502749. Epub 2019 Sep 24. Oncol Res Treat. 2019. PMID: 31550719 Clinical Trial.
Imatinib mesylate in chordoma.
Casali PG, Messina A, Stacchiotti S, Tamborini E, Crippa F, Gronchi A, Orlandi R, Ripamonti C, Spreafico C, Bertieri R, Bertulli R, Colecchia M, Fumagalli E, Greco A, Grosso F, Olmi P, Pierotti MA, Pilotti S. Casali PG, et al. Among authors: fumagalli e. Cancer. 2004 Nov 1;101(9):2086-97. doi: 10.1002/cncr.20618. Cancer. 2004. PMID: 15372471 Free article.
A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors.
Demetri GD, Casali PG, Blay JY, von Mehren M, Morgan JA, Bertulli R, Ray-Coquard I, Cassier P, Davey M, Borghaei H, Pink D, Debiec-Rychter M, Cheung W, Bailey SM, Veronese ML, Reichardt A, Fumagalli E, Reichardt P. Demetri GD, et al. Among authors: fumagalli e. Clin Cancer Res. 2009 Sep 15;15(18):5910-6. doi: 10.1158/1078-0432.CCR-09-0542. Epub 2009 Sep 1. Clin Cancer Res. 2009. PMID: 19723647 Free PMC article. Clinical Trial.
Adjuvant therapy of gastrointestinal stromal tumors (GIST).
Casali PG, Fumagalli E, Gronchi A. Casali PG, et al. Among authors: fumagalli e. Curr Treat Options Oncol. 2012 Sep;13(3):277-84. doi: 10.1007/s11864-012-0198-0. Curr Treat Options Oncol. 2012. PMID: 22743760 Review.
Are two better than one? A novel double-mutant KIT in GIST that responds to Imatinib.
Conca E, Miranda C, Dal Col V, Fumagalli E, Pelosi G, Mazzoni M, Fermeglia M, Laurini E, Pierotti MA, Pilotti S, Greco A, Pricl S, Tamborini E. Conca E, et al. Among authors: fumagalli e. Mol Oncol. 2013 Aug;7(4):756-62. doi: 10.1016/j.molonc.2013.02.019. Epub 2013 Mar 21. Mol Oncol. 2013. PMID: 23567324 Free PMC article.
148 results